Get Articles Daily from StraightStocks - Enter Email Address


  • National Debt Clock


Poppycock, Wiandt

Source: http://www.indexuniverse.com/blog/5936-poppycock-wiandt.html?Itemid=3&utm_source=straightstocks.com&utm_medium=sidebar&utm_campaign=rss
Posted on Tuesday, June 2nd, 2009 | In Exchange Traded Funds, Market Commentary
Contributed by: Matt Hougan (http://www.indexuniverse.com/sections/blog.html) -

Vanguard buying iShares, Jim? You have got to be kidding.

Your blog post on the topic smacks of desperation. The deal would “give Vanguard scale with intermediaries”? Please. Vanguard’s already building a nice intermediary business with its portfolio of 39 ETFs, thank you very much, and they don’t want/need another 150 products to sell.

The challenge of rationalizing those product lineups would be immense, and the numbers just don’t work for me. And as you so rightly point out, the ultimate question is how such a deal would benefit existing Vanguard shareholders, who own the firm. The answer is it wouldn’t.

What would make more sense—and something that Dave Nadig and I discussed briefly on our weekly podcast—is for Vanguard to swoop in and pick up the pieces of BGI after someone else carves out the iShares brand. The core BGI business would fit nicely into the Vanguard model, and help give it increasing scale and heft.

But iShares? Sorry.

BTW: By my calculations, the “go-shop” window for BGI ends two weeks from today. Barclays promises an update at that point.

Also: Impressive first day for Pimco’s new ETF, trading 300K shares. Whether it can hold that volume remains to be seen, but it shows that people are taking Pimco’s entry into the ETF space seriously.

 

Last 5 posts by Matt Hougan





About Matt Hougan (http://www.indexuniverse.com/sections/blog.html)
Matt Hougan is senior editor of the Journal of Indexes, editor of IndexUniverse.com and a contributing writer for the Exchange-Traded Funds Report and Financial Advisor magazine. Prior to joining JoI, Matt directed the internal communications effort at Genzyme Corporation, and worked as a biotech analyst and journalist for the award-winning financial Web site MetaMarkets.com.

Hougan, a 1998 graduate of Bowdoin College, lives on the coast of Maine.

Leave a Reply

Name

Email (kept private)

Website









No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.